NCT05209438 · RECRUITING

Cereset Research for Caregivers

This small pilot study tests whether Cereset, a device that plays sound tones through ear buds while tracking brain activity, can improve heart rate variability in stressed caregivers of people with dementia. It also looks at self-reported stress, sleep, and caregiver burden. It is an early pilot, so it is not proven or approved for anything.

You may qualify if

  • Participants must provide caregiving at least 10 hours per week. This includes all types of caregiving
  • participants must be willing to provide informed consent
  • participants must be able to comply with basic instructions
  • participants must be able to sit comfortably for up to 90 minutes, and attend up to three 60-minute intervention sessions each week during the 4-week intervention period
  • participants must self report experiencing symptoms of stress, anxiety, or insomnia and meet threshold scores on one or more self-report inventories of these symptoms (Insomnia Severity Index (ISI, ≥ 8), the Perceived Stress Index (PSS, ≥ 14), or the Generalized Anxiety Disorder 7-item (GAD-7, ≥ 5) scale)

You're excluded if

  • participants providing less than 10 hours a week of care to a person
  • participants who are unable or unwilling to attend intervention sessions during the planned study period
  • participants who are unable or unwilling to provide consent
  • participants who are not exhibiting symptoms of stress, anxiety or insomnia
  • participants with hearing impairment severe enough that they cannot perceive tones through ear buds
  • participants with known seizure disorder, or suicidal thoughts within the last 3 months
  • participants who respond positively to a question about risk for suicide within the last 3 months will be excluded and receive a behavioral health resource list
  • participants weighing more than 400 pounds (the weight limit of the chair used during intervention)
  • participants currently enrolled in another intervention study
  • prior use (past 3 years) of the technology being tested
  • prior use of neuromodulation, neurostimulation, deep brain stimulation, neurofeedback, biofeedback, alpha stim, Eye Movement Desensitization and Reprocessing (EMDR),or electroconvulsive therapy within the last month
  • Pace makers and beta blockers that affect the assessment of heart rate variability will also be exclusionary
  • participants taking Medications that may affect the assessment of heart rate variability (beta blockers.

The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.

Eligibility criteria as of 2026-06-01

View full record on ClinicalTrials.gov

All APOE4 clinical trials